注意缺陷多动障碍新药纳入优先审评近日,CDE官网公示,正式受理爱科百发新药丝右哌甲酯/右哌甲酯复方胶囊AK0901的新药上市申请(NDA),并将其纳入优先审评,拟定适应症为6岁及6岁以上注意缺陷多动障碍(ADHD)患者的治疗。公司资料显示,该药为目前唯一含有速释右哌甲酯(d-MPH)和前药丝右哌甲酯(SDX)的复方制剂,是针对ADHD患者的“Best-in-Class”创新治疗药物,2021年3月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.